secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2026-10-01T19:50:43+00:00
Accession:  0001493152-26-045341
Event type: m_and_a
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 2.01, 9.01, 3.02, 7.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Mangoceuticals' MangoRx IP sells 25% stake for $2.5M; $1.75M received, no MGRX shares issued
--------------------------------------------------------------------------------

- Two accredited investors agreed to buy an aggregate 25% membership interest in subsidiary MangoRx IP Holdings for $2.5M; $1.75M (17.5% post-transaction) already received.
- First investor paid $500,000 upfront in cash or Tether (USDT) plus $750,000 within 60 days; remaining 7.5% costs $750,000, due by November 28, 2026.
- No MGRX common stock, warrants or other parent securities issued; CEO Jacob Cohen says the deal preserves the public capitalization structure.
- MangoRx IP owns the MGX-0024 antiviral portfolio, led by U.S. Patent No. 11,517,523, with granted or pending patents in the EU, Canada, China, India, Australia and Japan.
- Company cites Fortune Business Insights 2025 markets of ~$34.8B for global oral care and ~$39.8B for feed additives as potential applications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/0001493152-26-045341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315226045341/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer